These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 24656909)

  • 41. Efficacy of SM-1 in a transient insomnia model.
    Dahl T; Chen LB; Zammit G; Ahmad M; Roth T
    Hum Psychopharmacol; 2019 Nov; 34(6):e2713. PubMed ID: 31837050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
    Karim A; Tolbert D; Cao C
    J Clin Pharmacol; 2006 Feb; 46(2):140-8. PubMed ID: 16432265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials.
    Yeung WF; Chung KF; Yung KP; Ng TH
    Sleep Med Rev; 2015 Feb; 19():75-83. PubMed ID: 25047681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ramelteon: a novel treatment for the treatment of insomnia.
    Wurtman R
    Expert Rev Neurother; 2006 Jul; 6(7):957-64. PubMed ID: 16831111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Imai N
    Intern Med; 2016; 55(17):2483-5. PubMed ID: 27580554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
    Liang L; Huang Y; Xu R; Wei Y; Xiao L; Wang G
    Sleep Med; 2019 Oct; 62():6-13. PubMed ID: 31518944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 48. Ramelteon-induced nightmares: A case report.
    Shah C; Kablinger A
    Asian J Psychiatr; 2015 Dec; 18():111-2. PubMed ID: 26427581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
    Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Iwata N
    PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease.
    Kryger M; Roth T; Wang-Weigand S; Zhang J
    Sleep Breath; 2009 Mar; 13(1):79-84. PubMed ID: 18584227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel.
    Zee PC; Wang-Weigand S; Wright KP; Peng X; Roth T
    Sleep Med; 2010 Jun; 11(6):525-33. PubMed ID: 20483660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder.
    Norris ER; Karen Burke ; Correll JR; Zemanek KJ; Lerman J; Primelo RA; Kaufmann MW
    J Affect Disord; 2013 Jan; 144(1-2):141-7. PubMed ID: 22963894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ramelteon (rozerem) a novel approach for insomnia treatment.
    Laustsen G; Andersen M
    Nurse Pract; 2006 Apr; 31(4):52-5. PubMed ID: 16607213
    [No Abstract]   [Full Text] [Related]  

  • 57. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
    Srinivasan V; Pandi-Perumal SR; Trahkt I; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
    Int J Neurosci; 2009; 119(6):821-46. PubMed ID: 19326288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis.
    Zheng Y; Lv T; Wu J; Lyu Y
    Sci Rep; 2022 Aug; 12(1):14453. PubMed ID: 36002579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and clinical safety of ramelteon: an evidence-based review.
    Sateia MJ; Kirby-Long P; Taylor JL
    Sleep Med Rev; 2008 Aug; 12(4):319-32. PubMed ID: 18603221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.